EDGE-GASTRIC


Associated tags: Patient, GEJ, Oxaliplatin, Safety, Biotechnology, Society, Conference, ASCO, Q&A, Gilead Sciences, Arm, FOLFOX, Abstract (summary), Pharmaceutical, American Society of Clinical Oncology, NYSE, Monthly, Other Health, Clinical Trials, Hospitals, Health, General Health

Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7

Retrieved on: 
Tuesday, October 17, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Hospitals, Clinical Trials, Other Health, Monthly, NYSE, American Society of Clinical Oncology, GEJ, Society, Abstract (summary), FOLFOX, Arm, Gilead Sciences, Q&A, ASCO, Conference, Patient, Pharmaceutical industry

Cohort A1 evaluates the combination of domvanalimab plus zimberelimab and chemotherapy given as an initial treatment in approximately 40 patients.

Key Points: 
  • Cohort A1 evaluates the combination of domvanalimab plus zimberelimab and chemotherapy given as an initial treatment in approximately 40 patients.
  • The ASCO Monthly Plenary Series is a virtual forum for presentation and discussion of the latest cancer research.
  • Abstracts accepted for the Monthly Plenary Session are also placed at the ASCO Annual Meeting in June 2024.
  • Following the release, Arcus management will host a conference call to discuss the financial results, EDGE-Gastric results and other pipeline updates.